The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Open accessAbstract
CONTEXT: Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood. OBJECTIVE: The aim of the study was to assess whether improvement in subclinical inflammation or glucose metabolism contributes to its antiatherogenic effects in insulin-resistant subjects with the metabolic syndrome (MetS). DESIGN AND SETTING: We conducted a randomized, double-blind, placebo-controlled study in the research unit at an academic center. PATIENTS: We studied 25 nondiabetic insulin-resistant MetS subjects. INTERVENTION(S): We administered fenofibrate (200 mg/d) and placebo for 12 wk. MAIN OUTCOME MEASURES: Before and after treatment, we measured plasma lipids/apolipoproteins, inflammatory markers (high-sensitivity C-reactive protein, IL-6, intercellular adhesion molecule/vascular cell adhesion molecule), adipocytokines (adiponectin, TNFalpha, leptin), and insulin secretion (oral glucose tolerance test). We also assessed adipose tissue, hepatic and peripheral (muscle) insulin resistance fasting and during a euglycemic insulin clamp with (3)H glucose and (14)C palmitate infusion combined with indirect calorimetry. RESULTS: Subjects displayed severe insulin resistance and systemic inflammation. Fenofibrate significantly reduced plasma triglyceride, apolipoprotein (apo) CII, apo CIII, and apo E (all P < 0.01), with a modest increase in high-density lipoprotein-cholesterol (+12%; P = 0.06). Fenofibrate markedly decreased plasma high-sensitivity C-reactive protein by 49.5 +/- 8% (P = 0.005) and IL-6 by 29.8 +/- 7% (P = 0.03) vs. placebo. However, neither insulin secretion nor adipose tissue, hepatic or muscle insulin sensitivity or glucose/lipid oxidation improved with treatment. Adiponectin and TNF-alpha levels were also unchanged. Improvement in plasma markers of vascular/systemic inflammation was dissociated from changes in triglyceride/high-density lipoprotein-cholesterol, apo CII/CIII, or free fatty acid concentrations or insulin secretion/insulin sensitivity. CONCLUSIONS: In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity. This suggests a direct peroxisome proliferator-activated receptor alpha-mediated effect of fenofibrate on inflammatory pathways, which may be important for the prevention of CVD in high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Robust Regression and Outlier Detection
Rousseeuw, P. J., & Leroy, A. M. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/0471725382 · Cited by 5,609
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationRubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B., & Rademaker, A. W. (2007) · Diabetes Care · doi:10.2337/dc07-0015 · Cited by 117
Research works printed but not linked: 26
- Cusi, 2001, Cardiovascular risk management in type 2 diabetes: from clinical trials to clinical practice, The Endocrinologist, 11, 474, 10.1097/00019616-200111000-00009 · DOI
- Caballero, 2004, Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes, Curr Diab Rep, 4, 237, 10.1007/s11892-004-0074-9 · DOI
- Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 · DOI · Paper page
- Plutzky, 2007, Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARα, Diab Vasc Dis Res, 4, S12, 10.3132/dvdr.2007.052 · DOI
- Shen, 1991, Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 73, 503, 10.1210/jcem-73-3-503 · DOI
- Avogaro, 2001, Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients, Eur J Clin Invest, 31, 603, 10.1046/j.1365-2362.2001.00856.x · DOI
- Damci, 2003, Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia, Eur J Intern Med, 14, 357, 10.1016/S0953-6205(03)90001-X · doi:10.1016/s0953-6205(03)90001-x
- Vuorinen-Markkola, 1993, Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 36, 161, 10.1007/BF00400699 · DOI
- Anderlová, 2007, Influence of PPAR-α agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes, Physiol Res, 56, 579, 10.33549/physiolres.931058 · DOI
- Abbasi, 2008, Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects, Am J Cardiol, 102, 64, 10.1016/j.amjcard.2008.02.097 · DOI
- Ridker, 2001, High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation, 103, 1813, 10.1161/01.CIR.103.13.1813 · DOI · Paper page
- Staels, 1998, Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators, Nature, 393, 790, 10.1038/31701 · DOI · Paper page
- Capell, 2003, Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia, Arterioscler Thromb Vasc Biol, 23, 307, 10.1161/01.ATV.0000046230.02211.B4 · DOI
- Rosenson, 2009, Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients, Obesity, 17, 504, 10.1038/oby.2008.530 · DOI
- Després, 2009, Bringing JUPITER down to earth, Lancet, 373, 1147, 10.1016/S0140-6736(09)60448-7 · DOI
- Chakravarthy, 2005, “New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis, Cell Metab, 1, 309, 10.1016/j.cmet.2005.04.002 · DOI · Paper page
- Haluzik, 2006, Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-α agonist treatment is accompanied by paradoxical increase of circulating resistin levels, Endocrinology, 147, 4517, 10.1210/en.2005-1624 · DOI
- Jones, 1990, Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM, Diabetes Care, 13, 855, 10.2337/diacare.13.8.855 · DOI
- Kim, 2003, Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis, Diabetes, 52, 1770, 10.2337/diabetes.52.7.1770 · DOI · Paper page
- Korenblat, Effects of fenofibrate and long-acting nicotinic acid on intrahepatic triglyceride content and adipose tissue insulin sensitivity in obese human subjects, 10.1016/S0168-8278(09)60059-3 · DOI
- Conjeevaram, 2009, A randomized, placebo-controlled study of PPAR-α agonist fenofibrate in patients with nonalcoholic steatohepatitis (NASH), Hepatology, 50, 774A
- Vega, 2003, Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome, Clin Pharmacol Ther, 74, 236, 10.1016/S0009-9236(03)00170-X · DOI
- Nelson, 2007, Splanchnic spillover of extracellular lipase-generated fatty acids in overweight and obese humans, Diabetes, 56, 2878, 10.2337/db07-0812 · DOI
- Vega, 2005, Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia, Am J Cardiol, 95, 1309, 10.1016/j.amjcard.2005.01.073 · DOI
- Ridker, 2007, C-reactive protein and the prediction of cardiovascular disease events among those at intermediate risk, J Am Coll Cardiol, 49, 2129, 10.1016/j.jacc.2007.02.052 · DOI · Paper page
- Marchesi, 2003, Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia, J Clin Pharm Ther, 28, 419, 10.1046/j.0269-4727.2003.00512.x · DOI
Cited by
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationCusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz-Lopez, C., Hecht, J., Feldstein, A. E., Webb, A., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.042 · Cited by 273
Self-citationNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136
Metadata
- Authors
- Belfort, R., Berria, R., Cornell, J., & Cusi, K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-02-01
- Volume
- 95
- Issue
- 2
- Pages
- 829-836
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2159962535
- Cited by
- 159
- References
- 8
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. https://app.cochat.ai/papers/10.1210/jc.2009-1487
- The paper
- Belfort, R., Berria, R., Cornell, J., & Cusi, K. (2010). Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-1487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.